GAINESVILLE, Fla., Aug. 26, 2014 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (Nasdaq:AGTC), a clinical-stage biotechnology company developing adeno-associated virus (AAV)-based gene therapy products for the treatment of rare eye diseases, today announced that Sue Washer, President and CEO will participate at the Citi 9th Annual Biotech Conference on Thursday, September 4th in a panel discussion entitled "Emerging Ophthalmology Therapies: Getting 20/20 on the Drug Landscape." The panel will be moderated by Citi analysts Yaron Werber and Liav Abraham.
AGTC is a clinical-stage biotechnology company that uses its proprietary gene therapy platform to develop products designed to transform the lives of patients with severe diseases in ophthalmology. AGTC's lead product candidates focus on X-linked retinoschisis, achromatopsia and X-linked retinitis pigmentosa, which are inherited orphan diseases of the eye, caused by mutations in single genes, that significantly affect visual function and currently lack effective medical treatments. AGTC has recently begun development of a product to treat Wet AMD using the company's experience in ophthalmology to expand into disease indications with larger markets.
CONTACT: David Carey Lazar Partners Ltd. T: (212) 867-1768 firstname.lastname@example.org Corporate Contact: Larry Bullock Chief Financial Officer Applied Genetic Technologies Corporation T: (386) 462-2204 email@example.com
Source:Applied Genetic Technologies